- Home
- IMAB vs ARVN Comparison
IMAB vs ARVN Comparison
Compare IMAB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ARVN
- Stock Information
- Founded
- IMAB 2014
- ARVN 2015
- Country
- IMAB United States
- ARVN United States
- Employees
- IMAB N/A
- ARVN N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ARVN Health Care
- Exchange
- IMAB Nasdaq
- ARVN Nasdaq
- Market Cap
- IMAB 384.6M
- ARVN 456.2M
- IPO Year
- IMAB 2020
- ARVN 2018
- Fundamental
- Price
- IMAB $3.69
- ARVN $7.61
- Analyst Decision
- IMAB Strong Buy
- ARVN Buy
- Analyst Count
- IMAB 5
- ARVN 22
- Target Price
- IMAB $6.80
- ARVN $20.02
- AVG Volume (30 Days)
- IMAB 1.7M
- ARVN 1.3M
- Earning Date
- IMAB 11-02-2025
- ARVN 10-29-2025
- Dividend Yield
- IMAB N/A
- ARVN N/A
- EPS Growth
- IMAB N/A
- ARVN N/A
- EPS
- IMAB N/A
- ARVN N/A
- Revenue
- IMAB N/A
- ARVN $372,800,000.00
- Revenue This Year
- IMAB N/A
- ARVN $1.61
- Revenue Next Year
- IMAB N/A
- ARVN N/A
- P/E Ratio
- IMAB N/A
- ARVN N/A
- Revenue Growth
- IMAB N/A
- ARVN 299.57
- 52 Week Low
- IMAB $0.60
- ARVN $5.90
- 52 Week High
- IMAB $5.90
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- IMAB 45.33
- ARVN 49.90
- Support Level
- IMAB $3.20
- ARVN $7.58
- Resistance Level
- IMAB $4.64
- ARVN $7.89
- Average True Range (ATR)
- IMAB 0.41
- ARVN 0.37
- MACD
- IMAB -0.17
- ARVN -0.03
- Stochastic Oscillator
- IMAB 29.88
- ARVN 18.42
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.